Compare BLMN & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLMN | IRWD |
|---|---|---|
| Founded | 1988 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 557.3M | 520.6M |
| IPO Year | 2012 | 2010 |
| Metric | BLMN | IRWD |
|---|---|---|
| Price | $6.18 | $3.37 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $8.50 | $5.34 |
| AVG Volume (30 Days) | 2.0M | ★ 2.3M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | ★ 7.29% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.18 |
| Revenue | ★ $3,952,793,000.00 | $338,987,000.00 |
| Revenue This Year | $2.19 | N/A |
| Revenue Next Year | $0.32 | $4.01 |
| P/E Ratio | ★ $16.56 | $19.03 |
| Revenue Growth | ★ 7.72 | N/A |
| 52 Week Low | $5.90 | $0.53 |
| 52 Week High | $12.97 | $4.78 |
| Indicator | BLMN | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 38.50 | 55.41 |
| Support Level | $6.45 | $3.11 |
| Resistance Level | $6.82 | $3.39 |
| Average True Range (ATR) | 0.26 | 0.20 |
| MACD | -0.08 | -0.06 |
| Stochastic Oscillator | 4.12 | 36.36 |
Bloomin Brands Inc operates as a casual dining restaurant company. The company's brand includes Outback Steakhouse, Carrabba's Italian Grill, Bonefish Grill, and Fleming's Prime Steakhouse and Wine Bar. The company owns and operates its restaurants, and the remainder is franchised. It derives revenue mainly from the United States, but the company has a presence in Brazil and South Korea with company-owned Outbacks and Carrabbas. In addition, it also has exposure to several countries, predominantly in Asia, principally through franchising. The Company aggregates its operating segments into two reportable segments, U.S. and international. The U.S. segment includes all restaurants operating in the U.S. while restaurants operating outside the U.S. are included in the international segment.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.